We are live on ! Find out more
LSTA icon

Lisata Therapeutics
LSTA

21 hedge funds and large institutions have $2.08M invested in Lisata Therapeutics in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more capital invested

Capital invested by funds: $1.8M → $2.08M (+$280K)

1.08% less ownership

Funds ownership: 9.22% → 8.14% (-1.1%)

13% less funds holding

Funds holding: 24 → 21 (-3)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
21
Holders Change
-3
Holders Change %
-12.5%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$1K
2
Barclays
Barclays
United Kingdom
+$7

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$173K
2
Citadel Advisors
Citadel Advisors
Florida
-$25.1K
3
UBS Group
UBS Group
Switzerland
-$19.7K
4
TRCT
Tower Research Capital (TRC)
New York
-$3.03K
5
IA
IFP Advisors
Florida
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
1
BML Capital Management
Indiana
$791K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$572K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$300K +$1K +300 +0.3%
BlackRock
4
BlackRock
New York
$184K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$84.4K – – –
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$48.6K – – –
State Street
7
State Street
Massachusetts
$46.6K – – –
CW
8
Cook Wealth
North Carolina
$39.6K – – –
Morgan Stanley
9
Morgan Stanley
New York
$5.03K – – –
TRCT
10
Tower Research Capital (TRC)
New York
$2K -$3.03K -905 -57%
FCMT
11
Founders Capital Management (Texas)
Texas
$2K – – –
Wells Fargo
12
Wells Fargo
California
$94 – – –
Bank of America
13
Bank of America
North Carolina
$84 -$67 -20 -43%
Northwestern Mutual Wealth Management
14
Northwestern Mutual Wealth Management
Wisconsin
$65 – – –
PCFFS
15
Pacific Center for Financial Services
California
$26 +$27 +8 New
Barclays
16
Barclays
United Kingdom
$19 +$7 +2 +50%
Osaic Holdings
17
Osaic Holdings
Arizona
$9 – – –
UBS Group
18
UBS Group
Switzerland
$3 -$19.7K -5,896 -100%
Fidelity Investments
19
Fidelity Investments
Massachusetts
$3 – – –
SM
20
Sabby Management
Florida
– -$173K -68,462 Closed
Citadel Advisors
21
Citadel Advisors
Florida
– -$25.1K -10,082 Closed
Group One Trading
22
Group One Trading
Illinois
– -$364 -146 Closed
IA
23
IFP Advisors
Florida
– -$2K -7 Closed

LSTA Hedge Fund Activity: Q1 2023 in Review

21 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q1 2023, worth a combined $2.08M — up 16% from $1.8M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of LSTA and 1 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, adding an estimated $1K. The largest seller was Sabby Management, exiting entirely with an estimated $173K sold.

  • 21 institutional investors held Lisata Therapeutics (LSTA) as of Q1 2023, down from 24 in Q4 2022.
  • Funds reported $2.08M of Lisata Therapeutics stock for Q1 2023, up 16% quarter-over-quarter.
  • 1 fund opened new Lisata Therapeutics positions in Q1 2023 and 4 closed out, a net change of -3 holders.
  • The largest Lisata Therapeutics buyer in Q1 2023 was Renaissance Technologies, an estimated $1K added.
  • The largest Lisata Therapeutics seller in Q1 2023 was Sabby Management, an estimated $173K sold.

Based on aggregated 13F filings for Q1 2023.